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Author's Personal CopyRESULTS: The prevalence of CAC was 58%. Patients without CAC showed lower TCB than
patients with CAC (298 6 110 vs 417.9 6 89 mmol-years/L, P , .001). Among patients aged
,45 years (n 5 56), 39% exhibited CAC and a higher TCB compared with patients without CAC
(352 6 71 vs 255 6 88 mmol-years/L, P , .001) due to higher TC levels at diagnosis (10.2 6 2
vs 8.7 6 2 mmol/L, P 5 .01). Multivariate analysis indicated that TCB was independently associated
to CAC.
CONCLUSIONS: Asymptomatic HeFH subjects exhibit early coronary atherosclerosis directly asso-
ciated with TCB burden. CAC score may be useful to identify higher risk HeFH patients who can
benefit from earlier and more aggressive treatment.
 2017 National Lipid Association. All rights reserved.Introduction
In Western countries, one over 200 people is affected by
heterozygous familial hypercholesterolemia (HeFH).1,2 In
this autosomal dominant genetic disorder, the early and
prolonged elevation of atherogenic lipoprotein particles
triggers the development of premature coronary artery dis-
ease (CAD)3; nevertheless, HeFH phenotype varies among
patients, some being more severe than others.4 The identi-
fication of HeFH patients at high cardiovascular risk (CVR)
is crucial for early treatment initiation as a 100-fold in-
crease in coronary heart disease (CHD) risk has been
observed in 20- to 39-years-old untreated HeFH patients.5
As recently pointed out, the characterization of severe FH
phenotypes is crucial for targeting a more aggressive treat-
ment since younger age.6 Common risk score calculators
are inadequate as they underestimate FH young patients
CVR by not accounting for lifelong elevated cholesterol
levels. Furthermore, currently recommended imaging tech-
niques for the detection of asymptomatic atherosclerosis
suffer from various drawbacks limiting their applicability
in young populations.
Coronary artery calcium (CAC) score measures athero-
sclerotic burden and predicts cardiovascular events in young
patients and in patients with familial history of cardiovascu-
lar disease.7,8 Lifelong exposure to cholesterol can be esti-
mated by the addition of yearly-obtained total cholesterol
(TC) levels to calculate total cholesterol burden (TCB).
Our aim was to use CAC score to evaluate coronary
atherosclerotic burden in patients with genetically diagnosed
HeFH and to study the relationship between CAC and TCB.Methods
Study population
Patients were consecutively recruited between May and
December 2015 at the Cardiovascular Prevention Unit at
Pitie-Salpe^triere Hospital in Paris, France.
Inclusion criteria were genetically confirmed HeFH,
age between 20 and 60 years, no symptoms or electrocar-
diographic signs of ischemia, no personal history of CHD,regular follow-up since diagnosis. Exclusion criteria were
no affiliation to a health care system, informed consent
refusal, contraindication to computed tomography (CT),
personal history of cardiovascular disease and myocardial
infarction, diabetes mellitus, uncontrolled hypertension or
triglycerides (TGs) . 4.5 mmol/L. We included only index
cases; relatives were excluded. The local institutional
review board approved the study and informed consent
was obtained from all included patients.
CAC measurements
Each patient underwent a multi-detector CT scan
(Definition Flash, Siemens, Erlangen, Germany) for a total
radiation exposure of 1 to 3 mSv. Coronary arteries were
imaged without contrast using helicoidal CT with prospec-
tive electrocardiographic gating. Monophasic mesodiastolic
imaging (75% of cardiac cycle) was performed when the
heart rate was under 85 bpm and replaced by systolic
imaging (40% of cardiac cycle) when heart rate was more
than 85 bpm to avoid right coronary artery motion artifacts.
Radiation dose was automatically adjusted to patient
morphology scout. Default voltage was 100 kV and
120 kV in overweight patients, and tube current was
automatically adapted according to patient morphology
(average 100–200 mAs) to minimize radiation dose. Slice
thickness reconstruction was 0.75 mm every 0.7 mm.
Typical total breath-holding time was from 10 to 15
seconds. CAC was quantified by means of the previously
described Agatston scoring method.9 The presence of CAC
was evaluated by semiautomated calcium scoring software
SyngoVia (Siemens, Erlangeen, Germany) over the entire
epicardial coronary tree. Briefly, coronary calcium was
defined as a lesion above a threshold of 130 Hounsfield
units, with an area of $3 adjacent pixels (at least
1 mm2). The CAC score was computed from the product
of the attenuation factor and the area of calcification
(square millimeter), with the total CAC score of each cor-
onary artery being equal to the sum CAC of all calcified
plaques from that artery. The total calcium score was calcu-
lated by summing CAC scores from the left main, left ante-
rior descending, left circumflex, and right coronary arteries.
All CT scans were quantified in an expert central reading
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(A.R.) who was blinded to patients FH status and TCB.
TCB calculation
Lifelong cholesterol exposure was calculated as TCB
(mmol-years/L) according to Schmidt et al.10 TCB is the
addition of cholesterol burden at diagnosis (dCB) and
post-diagnosis cholesterol burden (pdCB). dCB was ob-
tained by multiplying the initial serum TC value (before
treatment initiation) by the age of the patient at diagnosis.
pdCB was calculated by adding the TC values annually
measured during follow-up (on statin treatment) using pa-
tients’ medical records. For patients who were already on
treatment when genetic diagnosis was obtained, TCB was
calculated by multiplying the highest TC value before the
onset of statin treatment by patient’s age at clinical diag-
nosis. Missing TC values during follow-up were replaced
by the mean of all available TC values.
Risk factors assessment
Body mass index was measured as weight (kilograms)
divided by measured height (meters squared). Arterial
hypertension was defined as systolic blood pressure (SBP)
$140 mm Hg, diastolic blood pressure (DBP)$90 mm Hg,
and/or use of antihypertensive medication. Diabetes melli-
tus was defined as fasting plasma glucose (FPG) levels
$7.0 mmol/L or HbA1C . 6.5% and/or use of antidiabetic
treatment. Current smoking was defined as having smoked
at least 1 cigarette in the last 30 days.
Statistical analysis
Data are reported as mean 6 standard deviation (SD) for
continuous parametric and median (interquartile range) for
continuous nonparametric variables, and as frequency
(percentage) for categorical variables. Normality of contin-
uous variables distribution was tested using Shapiro-Wilk’s
test. Differences between groups were evaluated by anal-
ysis of variance. Distribution of categorical variables
between groups was evaluated using the chi-square test.
Correlations between 2 variables were assessed using a
linear regression model and Pearson’s correlation coeffi-
cient (r) or Spearman’s rho (for nonparametric variables)
were provided. CAC score was further studied for its
associations with TCB, SBP, sex (male 5 1), FPG, high-
density lipoprotein cholesterol (HDL-C), TG, smoking
status (current smoking 5 1), and statin treatment
(yes 5 1) using multivariate regression model. Age was
not considered separately as already included in the TCB
equation. The cubic root of CAC score was used for
parametrical tests.10 Study population was stratified by age
according to median age of 45 years. Statistical analyses
were performed using SAS software and a P value ,.05
was considered significant.Results
Table 1 summarizes the main clinical and biochemical
characteristics of the 112 patients, according to gender.
Mean time between age of HeFH diagnosis and CT scan
was 25 years and 82.1% of patients were under statin treat-
ment. Median overall CAC score was 9.1 (0–148) and
males had a higher CAC score compared with females (me-
dian 59.7 vs 0.0, respectively, P , .01). The overall preva-
lence of CAC was 58.1%, being higher in males than in
females (P 5 .04). No differences were found between gen-
ders in terms of age, TCB, body mass index as well as xan-
thomas, mutation type, smoke, and hypertension
prevalence. Higher TC, HDL-C, and apolipoprotein-A1
levels, as well as lower TG were observed in females,
whereas a higher proportion of males were under lipid-
lowering treatment.
Main characteristics of the study population, stratified
by presence or absence of CAC, are shown in Table 2.
Patients with CAC exhibited higher TCB than patients
without CAC (417.9 6 89 vs 298.0 6 110 mmol-years/L,
P , .001). Patients with CAC were more likely to be males
and older, with a higher prevalence of xanthomas and hy-
pertension. At diagnosis, they also presented with a higher
age and TC. Compared with patients without CAC, they
had higher Low-density lipoprotein (LDL) cholesterol
(LDL-C; P , .05), TC, Apo-B, and TG (P , .02) levels.
Among patients with LDL receptor (LDLR) mutations,
47 (45.2%) had a null mutation, and 57 (54.8%) a defective
mutation. No differences were found in CAC prevalence
according to the residual LDLR function. Lipoprotein(a)
was not associated with TCB or CAC, either as a dichoto-
mous and a continuous variable.
TBC was significantly related with all 3 commonly used
scores for clinical diagnosis of FH (Dutch Lipid Clinic
Network, Simon-Broome, or Make Early Diagnosis to
Prevent Early Deaths), even though the Simon-Broome
showed the strongest association (R2 5 0.645, P 5 .00001;
Supplementary Table 1). Conversely, the CAC score levels
were significantly associated only with Dutch Lipid Clinic
Network scores (R2 5 0.193, P 5 .014) in a model that
included age.
Noteworthy, according to all 3 CVR scores, the cohort
was at low risk (median [interquartile range], SCORE 0.0%
[0.0–1.1]; Framingham 2.1% [0.375–6.05]; atherosclerotic
cardiovascular disease 2.2% [1.0–4.9]). CAC was present in
about half of patients identified as low CVR by common
CVR equations (Supplementary Table 2). To this regard,
about 20% of HeFH patients classified as at low-risk pa-
tients had CAC. 100. This was observed also in the young
subgroup (Supplementary Table 3).
When stratified according to the median age of 45 years,
patients aged ,45 years exhibited a 39% prevalence of
CAC (Fig. 1).
Furthermore, HeFH patients aged ,45 years with CAC
had a higher dCB and TCB compared with patients without
CAC in the same age range (Fig. 2).
Table 1 Patient characteristics according to gender
All (n 5 112) Males (n 5 56) Females (n 5 56)
Age, y 44.5 (38–52) 44 (36–51) 46.5 (38–55)
BMI (kg/m2) 24.4 (21–27) 25.4 (23–28) 23.4 (20–27)
Subclinical atherosclerosis burden
CAC score 0, n (%) 58 (51.8) 23 (41.1) 35 (62.5)‡
CAC score 1–100, n (%) 22 (19.6) 10 (17.8) 12 (21.4)
CAC .100, n (%) 32 (28.6) 23 (41.1) 9 (16.1)*
Cholesterol burden
Cholesterol burden at diagnosis, mmol-years/L 187.6 6 118 186.9 6 134 188.4 6 100
Cholesterol burden postdiagnosis, mmol-years/L 182.0 6 87 175.3 6 87 188.7 6 88
Total cholesterol burden, mmol-years/L 363.7 6 114 359.6 6 132 374.5 6 94
FH history
Mutation type (LDLR/ApoB/PCSK9; n) 104/7/1 51/4/1 53/3/-
Age of diagnosis, y 18.0 (11–27) 16 (10–29) 18 (12–23)
TC at diagnosis, mmol/L 9.6 (8–11) 9.0 (7.9–11.6) 9.8 (8.3–10.6)
Xanthomas, n (%) 27 (24.1) 13 (23.2) 14 (25)
Cardiovascular risk factors
Current smoking, n (%) 34 (30.4) 19 (34) 15 (26.7)
Arterial hypertension, n (%) 11 (9.8) 7 (12.5) 4 (7.1)
Lipid profile
TC, mmol/L 6.2 (5–7) 5.6 (5–6.6) 6.6 (6–7)‡
TG, mmol/L 1.0 (0.7–1.3) 1.1 (1–1.5) 0.9 (0.7–1.3)*
HDL-C, mmol/L 1.3 (1–1.6) 1.2 (1–1.4) 1.5 (1–2)x
LDL-C, mmol/L 4.1 (3.6–5) 3.9 (4–5) 4.2 (4–5.5)
ApoB, mg/dL 116.0 (103–137) 116.0 (101.5–137) 117.0 (103–214)
ApoA1, mg/dL 145.0 (131–163) 140.0 (126–152) 149.5 (137–166)*
Lp(a), mg/dL 26.0 (12–51) 21.5 (9–45) 27.0 (13–53)
Current lipid-lowering treatment
Overall, n (%) 92 (82.1) 53 (94.6) 39 (69.6)*
Statins, n (%) 90 (80.3) 52 (92.8) 38 (67.8)*
Ezetimibe, n (%) 38 (33.9) 24 (42.8) 14 (25)†
ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; BMI, body mass index; CAC, coronary artery calcium; FH, familial hypercholesterolemia; HDL-C,
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LDL-R, low-density lipoprotein cholesterol receptor; Lp(a), lipoprotein
(a); SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides.
Data are expressed as mean 6 standard deviation or median (interquartile range).*P , .01; †P , .05; ‡P , .02; xP , .001; males vs female.
Cholesterol burden at diagnosis was calculated as age! TC at diagnosis; Cholesterol burden postdiagnosis was calculated as the sum of one value of
TC per year since diagnosis; Total cholesterol burden is the sum of cholesterol burden at diagnosis and cholesterol burden postdiagnosis.
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diagnosis (10.2 6 2 vs 8.7 6 2 mmol/L, P 5 .01) while
age at diagnosis was not different (11 vs 15 years,
P 5 .09). Postdiagnosis CB was not different between the
2 subgroups. No differences in TCB, dCB, and pdCB
were found between patients aged $45 years with CAC
vs patients without CAC.
Univariate analysis showed that CAC presence was
associated with TCB (R2 5 0.330, P , .001), pdCB
(R2 5 0.248, P , .001), and dCB (adjusted R2 5 0.156,
P 5 .001). When considered separately, both age and
TCB were found to be positively correlated to CAC (Spear-
man’s rho 5 0.462 and 0.500, respectively. P , .001).
Multivariate analysis (Table 3) indicated that TCB was
associated to CAC score levels independently from gender,
smoking status, statin treatment, HDL-C, TG, FPG, and
SBP levels (P , .001).Discussion
In this study, asymptomatic genetically determined
HeFH patients were found to have a high prevalence of
CAC. Lifelong cholesterol accumulation, measured by the
TCB, was independently associated to this premature CAC
detection.
These findings are in line with 2 previous reports of
early calcified coronary plaques in clinically diagnosed
HeFH evaluated by electron-beam tomography11 and CT
scan.12 In the latter study, the prevalence of HeFH patients
with CAC was below 50%, which is comparable to our
results.
Presence of CAC has been associated to a higher risk of
CHD in asymptomatic patients with dyslipidemia13 or with
family history of CHD.8 The prevalence of CAC in our
cohort was much higher than that found in the CARDIA
Table 2 Characteristics of patients with and without CAC
CAC 0 (n 5 47) CAC .0 (n 5 65)
Gender, n male/n female 18/29 38/27*
Age, y 38 (28–46) 48.5 (43–53)†
BMI, kg/m2 22.6 (20–27) 25.6 (23–28)
CAC score 0 161.75 (32–375)
Cholesterol burden
Cholesterol burden at diagnosis, mmol-years/L 145.5 6 111 217.3 6 114†
Cholesterol burden postdiagnosis, mmol-years/L 155.6 6 78 199.6 6 89†
Total cholesterol burden, mmol-years/L 298 6 110 417.9 6 89†
FH history
Mutation type (LDLR/ApoB/PCSK9), n 45/2/- 59/5/1
Age of diagnosis, y 15 (8–22) 20 (15–30)*
TC at diagnosis, mmol/l 8.4 (7–10) 10.3 (8–12)†
Xanthomas, n (%) 7 (14.9) 20 (30.7)‡
Cardiovascular risk factors
Current smoking, n (%) 13 (27.7) 21 (32.3)
Arterial hypertension, n (%) 1 (2.1) 10 (15.4)*
Lipids levels
TC, mmol/L 5.7 (5–7) 6.4 (6–7.3)x
TG, mmol/L 0.9 (0.7–1.2) 1.1 (0.8–1.5)x
HDL-C, mmol/L 1.2 (1–1.5) 1.3 (1.2–1.6)
LDL-C, mmol/L 3.9 (3.6–5) 4.2 (3.8–5.4)*
ApoB, mg/dL 110.0 (101–124) 121.0 (105–147)x
ApoA1, mg/dL 136.0 (127–157) 149.0 (132–163)
Lp(a), mg/dL 26.0 (12–50) 25.0 (9–51)
Current lipid treatment
Statin, n (%) 35 (74.5) 55 (84.6)
Ezetimibe, n (%) 7 (14.9) 31 (47.7)†
ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; BMI, body mass index; CAC, coronary artery calcium; FH, familial hypercholesterolemia; HDL-C,
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LDLR, low-density lipoprotein cholesterol receptor; Lp(a), lipoprotein
(a); SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides.
*P , .05; †P , .001; ‡P , .01; xP , .02 vs CAC 0.
Cholesterol burden at diagnosis was calculated as age ! TC at diagnosis.
Cholesterol burden postdiagnosis was calculated as the sum of one cholesterol per year since diagnosis. Total cholesterol burden is the sum of
cholesterol burden at diagnosis and cholesterol burden postdiagnosis.
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Author's Personal Copystudy, where only 9.9% of 2832 patients aged 33 to 45 years
exhibited coronary calcifications.14 Furthermore, the pres-
ence of CAC in about a half of patients classified as at
low risk by common CVR equations suggest that CAC
evaluation could have a real incremental value beyond
risk algorithms. However, the final incremental value could
only be determined with long-term prospective trial.
Typically, CAC scanning is not used for individuals aged
,45 years because most atherosclerotic plaques are not
calcified in younger individuals, but in our high-risk
population, 39% of individuals with HeFH aged
,45 years already had CAC. The large reference Multi-
Ethnic Study of Atherosclerosis (MESA) only enrolled
individuals aged .45 years, therefore presence of CAC
would be a high-risk score for MESA adults aged 45 to
50 years.15
The absence of CAC has been associated with a low risk
of CHD.16 In the Dallas Heart Study cohort of young pa-
tients with a family history of CHD, the overall absence
of CAC (47%) was associated to a 0.4% to 1.9% CHDrate. However, in this study, the presence of HeFH, often
associated with a family history of CHD, was not assessed.8
In a cohort of 140 clinically diagnosed HeFH asymptomatic
patients (mean age 52 years, known genetic disorder in
66% of the cohort, diabetes prevalence 6%), only 21%
were found without CAC. They underwent CT angiography
and no plaques were found, whereas 69% of patients with a
CAC score .400 exhibited obstructive CAD.17
Apart from CAC, some clinical parameters have shown
to be useful in HeFH patients for CVD risk refinement.
Among them lipoprotein(a) has been associated with
early CHD also in FH18 and can be used for risk reclassi-
fication.19 Contrarily, while a null mutation has been
associated with an increased prevalence of premature
CVD and recurrence of CV events compared with a defec-
tive LDLR mutation,20 no significant associations were
found between mutation type and aortic/carotid plaque
presence.21
Our results in HeFH with an established genetic diag-
nosis reinforce the concept of an association between early,
Table 3 Multivariate analysis of CAC score determinants
Calcium score
R2 b P
Overall model 0.29 .0001
Gender (male 5 1) 1.98 6 0.7 .005
Total cholesterol
burden,
mmol-years/L
0.01 6 0.003 .0001
Current smoking
(yes 5 1)
0.5 6 0.64 .42
Statin treatment
(yes 5 1)
0.38 6 0.81 .64
HDL-C, mmol/L 0.1 6 0.7 .9
TG, mmol/L 0.33 6 0.5 .5
FPG, mmol/L 0.29 6 0.63 .65
SBP, mm Hg 20.002 6 0.031 .98
FPG, fasting plasma glucose; HDL-C, high-density lipoprotein
cholesterol; SBP, systolic blood pressure; TG, triglycerides.
Figure 1 Prevalence of CAC in patients aged ,45 and
.45 years. *P , .001 vs absence of CAC. CAC, coronary artery
calcium; HeFH, heterozygous familial hypercholesterolemia.
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shown in non-HeFH subjects of the Framingham offsprings
cohort.22 Here, in HeFH subjects, we showed an indepen-
dent association between TCB and calcified coronary
atherosclerotic burden that expands previous results on arte-
rial stiffening and thickening.23 In young patients aged
,45 years, we report the high prevalence of CAC presence
in correlation with the cholesterol burden at diagnosis sug-
gesting a potential role of early exposure to elevated choles-
terol levels. The strength of our study is the inclusion of
HeFH who have been genetically diagnosed, early treated,
and regularly followed in our unit since diagnosis. This
enabled us to limit potential bias in cholesterol burden
calculation and to present results in a very well–character-
ized population.Figure 2 Cholesterol burden in patients aged , 45 years (left)
and $45 years (right) with or without CAC. *P , .02;
**P , .001 vs absence of CAC. Patients aged , 45 years:
CAC 5 0 (n 5 34); CAC . 0 (n 5 22). Patients aged
$45 years: CAC 5 0 (n 5 13); CAC . 0 (n 5 43).Cholesterol burden at diagnosis can be easily calculated
and may be helpful beyond single TC levels to identify
higher risk HeFH patients who could benefit from a
more aggressive lipid-lowering treatment (eg, high-dose
statin 1 ezetimibe, PCSK9 inhibitors, and/or lomitapide).
The dCB calculation (TC levels at diagnosis ! age at
diagnosis) assumes that TC levels are a constant throughout
early life, which may raise some doubts. However, during
the 27 years of follow-up of the Bogalusa Heart Study,
66.2% of the dyslipidemic subjects in the 2 highest
quintiles for non–HDL-C levels remained in the same
quintiles during adulthood.24
The early appearance of calcified plaques in HeFH can
be explained by several mechanisms. First, the LDLR itself
may have a potential role in determining a higher
prevalence of calcifications in young HeFH patients. A
crosstalk between LDLR and LDL-related protein 5/6 may
take place that would allow the nuclear translocation of
beta-catenin in the osteocyte, determining calcium deposi-
tion in the vascular wall.25 Our results also confirm previ-
ously data published by Borholt-Petersen et al. where no
influence of the type of LDLR mutation (null vs defective)
was associated with a more severe vascular phenotype.26
Statins have been shown to prevent atherosclerotic plaques
development but also to enhance their calcifications.27
Eighty percent of our patients were under statin treatment:
on the one hand, this may have explained the relatively
high prevalence of calcified plaques in our younger
subgroup of HeFH patients; on the other hand, an early
treatment initiation may have accounted for the 61% prev-
alence of zero CAC in the younger. However, in the multi-
variate analysis, statin treatment was not associated with
CAC. Novel recommendations suggest, for HeFH, a treat-
ment goal LDL-C ,1.8 mmol/L for patients at high risk
due to the evidence of CVD or a severe FH phenotype28
suggestive of a delayed diagnosis and/or treatment. CAC
710 Journal of Clinical Lipidology, Vol 11, No 3, June 2017
Author's Personal Copyscanning could be a useful tool in HeFH patients’ upward
CVR reclassification, to identify those individuals who
could benefit from a statin-ezetimibe combination or
PCSK9 antibodies therapy. Moreover, in this age of
electronic medical records, a measure of TCB could be
generated as a tool for clinicians to identify high-risk indi-
viduals who might warrant early and more intensified
prevention.
Our study exhibits some limitations. First, it is a cross-
sectional study on a small genetically selected population.
However, it enabled accurate phenotyping and TCB
calculation.
The concept of TCB may be considered controversial in
FH patients because they are exposed to very high
cholesterol levels since birth. However, even in our cohort
of genetically classified, early treated, and regularly
followed-up HeFH patients, we were able to observe that
treatment initiation has an effect in reducing TCB.
CT angiography, the gold standard for coronary plaque
detection, was not performed. Although this may have
allowed hypodense noncalcified plaques detection, CT
angiography requires contrast injection and a higher radi-
ation exposure. In terms of risk reclassification, it did not
lead to an improvement when compared with a model
based on standard risk factors and CAC in a registry of
asymptomatic non-HeFH29 or HeFH subjects with other
CVR factors.12,17 Finally, we did not compare HeFH to a
control group. However, we used the same age non-HeFH
CARDIA study cohort to compare the prevalence of
CAC. Furthermore, validated age- and gender-adjusted
nomograms from the MESA were used in which young
patients with CAC . 0 fall in the 75th percentile to postu-
late that having CAC aged ,45 years indicates high
CVR.15
In conclusion, young asymptomatic HeFH subjects
exhibit early calcified coronary atherosclerosis in associa-
tion with lifelong exposure to high cholesterol levels. TCB
calculation at the time of diagnosis may be useful to
identify more severe phenotypes of HeFH patients who
could benefit from a more aggressive lipid-lowering
therapy as advocated by recent guidelines. In this accu-
rately selected population of genetically confirmed HeFH
patients, CAC score may therefore contribute to tailor more
aggressive LDL-C lowering strategies aiming at reaching
LDL-C target.
Acknowledgment
Authors0 contributions: All authors contributed to
conception, design, drafting and final revision and approval
of the article. A.G., P.G., E.B., and D.R. provided to data
collection and analysis; A.C. performed genetic analysis;
A.R. analyzed all CT images for CAC score calculation;
R.B. provided lipid and biochemical profiling.
Funding sources: This research did not receive any
specific grant from funding agencies in the public, com-
mercial, or not-for-profit sectors.Disclosure
E.B. declares having received honoraria from
AstraZeneca, AMGEN, Genfit, MSD, Sanofi and Regen-
eron, Unilever, Danone, Aegerion, Chiesi, Rottapharm-
MEDA, Lilly, Ionis-pharmaceuticals; D.R. declares having
received honoraria from AMGEN (Research Grant), Sanofi,
Novartis, Roche, AMGEN, Daiichi Sankyo, MSD (Fees for
lecture/consulting and travel grants). Remaining authors
have nothing to disclose.References
1. Benn M, Watts GF, Tybjærg-Hansen A, Nordestgaard BG. Mutations
causative of familial hypercholesterolaemia: screening of 98 098 indi-
viduals from the Copenhagen General Population Study estimated a
prevalence of 1 in 217. Eur Heart J. 2016;37(17):1384–1394.
2. Nordestgaard BG, Chapman MJ, Humphries SE, et al, for the Euro-
pean Atherosclerosis Society Consensus Panel. Familial hypercholes-
terolaemia is underdiagnosed and undertreated in the general
population: guidance for clinicians to prevent coronary heart disease:
consensus statement of the European Atherosclerosis Society. Eur
Heart J. 2013;34(45):3478–3490a.
3. Hutter CM, Austin MA, Humphries SE. Familial hypercholesterole-
mia, peripheral arterial disease, and stroke: a HuGE minireview. Am
J Epidemiol. 2004;160(5):430–435.
4. Sniderman AD, Tsimikas S, Fazio S. The severe hypercholesterolemia
phenotype: clinical diagnosis, management, and emerging therapies. J
Am Coll Cardiol. 2014;63(19):1935–1947.
5. Risk of fatal coronary heart disease in familial hypercholesterolemia.
Scientific Steering Committee on behalf of the Simon Broome Regis-
ter Group. BMJ. 1991;303(6807):893–896.
6. Sharifi M, Rakhit RD, Humphries SE, Nair D. Cardiovascular risk
stratification in familial hypercholesterolemia. Heart. 2016;102(13):
1003–1008.
7. Rana JS, Gransar H, Wong ND, et al. Comparative value of coronary
artery calcium and multiple blood biomarkers for prognostication of
cardiovascular events. Am J Cardiol. 2012;109(10):1449–1453.
8. Paixao ARM, Berry JD, Neeland IJ, et al. Coronary artery calcification
and family history of myocardial infarction in the Dallas Heart Study.
JACC Cardiovasc Imaging. 2014;7(7):679–686.
9. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M,
Detrano R. Quantification of coronary artery calcium using ultrafast
computed tomography. J Am Coll Cardiol. 1990;15(4):827–832.
10. Schmidt HH, Hill S, Makariou EV, Feuerstein IM, Dugi KA, Hoeg JM.
Relation of cholesterol-year score to severity of calcific atherosclerosis
and tissue deposition in homozygous familial hypercholesterolemia.
Am J Cardiol. 1996;77(8):575–580.
11. Gidding SS, Bookstein LC, Chomka EV. Usefulness of electron beam
tomography in adolescents and young adults with heterozygous famil-
ial hypercholesterolemia. Circulation. 1998;98(23):2580–2583.
12. Miname MH, Ribeiro MS, Parga Filho J, et al. Evaluation of subclin-
ical atherosclerosis by computed tomography coronary angiography
and its association with risk factors in familial hypercholesterolemia.
Atherosclerosis. 2010;213(2):486–491.
13. Martin SS, Blaha MJ, Blankstein R, et al. Dyslipidemia, coronary ar-
tery calcium, and incident atherosclerotic cardiovascular disease: im-
plications for statin therapy from the multi-ethnic study of
atherosclerosis. Circulation. 2014;129(1):77–86.
14. Okwuosa TM, Greenland P, Ning H, Liu K, Lloyd-Jones DM. Yield of
screening for coronary artery calcium in early middle-age adults based
on the 10-year Framingham Risk Score: the CARDIA study. JACC
Cardiovasc Imaging. 2012;5(9):923–930.
15. McClelland RL, Chung H, Detrano R, Post W, Kronmal RA. Distribu-
tion of coronary artery calcium by race, gender, and age: results from
Gallo et al Early atherosclerosis in hypercholesterolemia 711
Author's Personal Copythe Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2006;
113(1):30–37.
16. Nasir K, Budoff MJ, Wong ND, et al. Family history of premature cor-
onary heart disease and coronary artery calcification: Multi-Ethnic
Study of Atherosclerosis (MESA). Circulation. 2007;116(6):619–626.
17. Neefjes LA, Ten Kate G-JR, Alexia R, et al. Accelerated subclinical
coronary atherosclerosis in patients with familial hypercholesterole-
mia. Atherosclerosis. 2011;219(2):721–727.
18. Alonso R, Andres E, Mata N, et al, for the SAFEHEART Investiga-
tors. Lipoprotein(a) levels in familial hypercholesterolemia: an impor-
tant predictor of cardiovascular disease independent of the type of
LDL receptor mutation. J Am Coll Cardiol. 2014;63(19):1982–1989.
19. Nordestgaard BG, Chapman MJ, Ray K, et al, for the European
Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardio-
vascular risk factor: current status. Eur Heart J. 2010;31(23):
2844–2853.
20. Alonso R, Mata N, Castillo S, et al, on behalf of the Spanish Familial
Hypercholesterolaemia Group. Cardiovascular disease in familial hy-
percholesterolaemia: influence of low-density lipoprotein receptor mu-
tation type and classic risk factors. Atherosclerosis. 2008;200(2):
315–321.
21. Caballero P, Alonso R, Rosado P, et al. Detection of subclinical athero-
sclerosis in familial hypercholesterolemia using non-invasive imaging
modalities. Atherosclerosis. 2012;222(2):468–472.
22. Navar-Boggan AM, Peterson ED, D’Agostino RB, Neely B,
Sniderman AD, Pencina MJ. Hyperlipidemia in early adulthood in-
creases long-term risk of coronary heart disease. Circulation. 2015;
131(5):451–458.23. Cheng HM, Ye ZX, Chiou KR, Lin SJ, Charng MJ. Vascular stiffness
in familial hypercholesterolaemia is associated with C-reactive protein
and cholesterol burden. Eur J Clin Invest. 2007;37(3):197–206.
24. Srinivasan SR, Frontini MG, Xu J, Berenson GS. Utility of childhood
non-high-density lipoprotein cholesterol levels in predicting adult dys-
lipidemia and other cardiovascular risks: the Bogalusa Heart Study.
Pediatrics. 2006;118(1):201–206.
25. Pugliese G, Iacobini C, Blasetti Fantauzzi C, Menini S. The dark and
bright side of atherosclerotic calcification. Atherosclerosis. 2015;
238(2):220–230.
26. Brorholt-Petersen JU, Jensen HK, Jensen JM, et al. LDL receptor mu-
tation genotype and vascular disease phenotype in heterozygous famil-
ial hypercholesterolaemia. Clin Genet. 2002;61(6):408–415.
27. Puri R, Nicholls SJ, Shao M, et al. Impact of statins on serial coronary
calcification during atheroma progression and regression. J Am Coll
Cardiol. 2015;65(13):1273–1282.
28. Santos RD, Gidding SS, Hegele RA, et al, International Atheroscle-
rosis Society Severe Familial Hypercholesterolemia Panel. Defining
severe familial hypercholesterolaemia and the implications for clinical
management: a consensus statement from the International Athero-
sclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet
Diabetes Endocrinol. 2016;4(10):850–861.
29. Cho I, Chang H-J, O Hartaigh B, et al. Incremental prognostic utility
of coronary CT angiography for asymptomatic patients based upon
extent and severity of coronary artery calcium: results from the COr-
onary CT Angiography EvaluatioN For Clinical Outcomes InteRna-
tional Multicenter (CONFIRM) study. Eur Heart J. 2015;36(8):
501–508.
Supplementary Table 2 Number of subjects for each cardiovascular risk score class, according to presence/absence and intensity
of CAC
Score Framingham ASCVD
Low
(,1%)
Moderate
(1%–4.9%)
High
($5%) Total
Low
(,10%)
Intermediate
(10%–19.9%)
High
($20%) Total
Low
(,5%)
Intermediate
(5%–7.49%)
High
($7.5%) Total
Presence of CAC
CAC 0, n 40 8 0 48 46 1 1 48 41 7 0 48
CAC . 0, n 31 33 0 64 50 10 4 64 44 8 12 64
Total 71 41 0 112* 94 11 5 112† 85 15 12 112‡
Intensity of CAC
CAC 0, n 49 9 0 48 46 1 1 48 41 7 0 48
CAC 1–100, n 19 13 0 32 27 4 1 32 26 3 3 32
CAC .100, n 12 20 0 32 23 6 3 32 18 5 9 32
Total 71 41 0 112* 96 11 5 112 85 15 12 112x
ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcification.
Chi-squared test: *P 5 .000; †P 5 .03; ‡P 5 .002; xP 5 .006.
Supplementary Table 1 Univariate analysis of determinants of total CB, CB at diagnosis and postdiagnosis
DLCN Simon-Broome MEDPED
R2 P R2 P R2 P
Total cholesterol burden 0.625 .001 0.645 .000 0.603 .041
Diagnosis cholesterol burden 0.351 .043 0.327 .629 0.331 .391
Postdiagnosis cholesterol burden 0.123 .7 0.231 .000 0.176 .009
CB, cholesterol burden; DLCN, Dutch Lipid Clinic Network; MEDPED, Make Early Diagnosis to Prevent Early Deaths.
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Supplementary Table 3 Number of HeFH subjects in the under 45 subgroup for each cardiovascular risk score class, according to
presence or absence and intensity of CAC
Score Framingham ASCVD
Low
(,1%)
Moderate
(1%–4.9%)
High
($5%) Total
Low
(,10%)
Intermediate
(10%–19.9%)
High
($20%) Total
Low
(,5%)
Intermediate
(5%–7.49%)
High
($7.5%) Total
Presence of CAC
CAC 0, n 31 3 0 34 33 0 1 34 31 3 0 34
CAC . 0, n 18 4 0 22 19 3 0 22 20 2 0 22
Total 49 7 0 56 52 3 1 56 51 5 0 56
Intensity of CAC
CAC 0, n 31 3 0 34 33 0 1 34 31 3 0 34
CAC 1–100, n 13 1 0 14 13 1 0 14 14 0 0 14
CAC .100, n 5 3 0 8 6 2 0 8 6 2 0 8
Total 49 7 0 56 50 3 1 56* 51 5 0 56
ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcification.
Chi-squared test: *P 5 .03.
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